ABBOTT LABORATORIES 8-K

What Happened

• Abbott Laboratories (ABT) filed an 8‑K reporting board and shareholder actions from its April 24, 2026 Annual Meeting. Kevin Conroy was named to Abbott’s Board of Directors, and the Board amended the by‑laws to set the board size at thirteen effective April 24, 2026.
• Shareholders approved the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”), which was adopted by the Board on February 20, 2026 subject to shareholder approval. The 2026 Program replaces the 2017 Incentive Stock Program, has a 10‑year term, is administered by the Compensation Committee, and authorizes up to 140,000,000 Abbott common shares (subject to certain capitalization adjustments) for equity awards (options, restricted stock, RSUs, performance awards and related award types).

Key Details

• New director appointment: Kevin Conroy named to the Board, effective April 24, 2026. By‑laws amended to increase Board size from 12 to 13.
• 2026 Incentive Stock Program: maximum of 140,000,000 shares (plus adjustments); 10‑year term; permits nonqualified stock options, restricted stock awards/units, performance awards, SARs, dividend equivalents and recognition awards.
• Shareholder votes at the April 24, 2026 meeting:
  • 2026 Incentive Stock Program approved: 1,303,349,739 FOR; 52,296,340 AGAINST; 4,463,763 ABSTAIN; 177,761,396 broker non‑votes.
  • Say‑on‑pay (advisory compensation vote) approved: 1,228,911,693 FOR (90.35% of votes cast); 126,315,146 AGAINST; 4,883,003 ABSTAIN; 177,761,396 broker non‑votes.
  • Auditor ratification (Ernst & Young LLP) approved: 1,502,083,607 FOR; 33,333,515 AGAINST; 2,454,116 ABSTAIN.
  • 2026 Employee Stock Purchase Plan for Non‑U.S. Employees approved: 1,351,008,136 FOR; 6,111,112 AGAINST; 2,990,594 ABSTAIN; 177,761,396 broker non‑votes.
• The filing includes amended by‑laws (effective April 24, 2026) and multiple award agreement forms as exhibits.

Why It Matters

• Equity plan adoption can affect share dilution and executive/board compensation structure: the new 2026 Program authorizes up to 140 million shares (plus adjustments) over its 10‑year term, which investors should monitor when assessing potential dilution and outstanding share count trends.
• Governance update: adding a director and increasing board size may affect oversight and strategy; strong shareholder support for the equity plan and say‑on‑pay (large FOR vote counts) indicates backing for current compensation policies and governance actions at the Annual Meeting.